STOCK TITAN
  1. Home
  2. News
  3. PFE

Pfizer Inc. - PFE STOCK NEWS

Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.

Pfizer Inc. (PFE), headquartered at The Spiral in Manhattan, New York City, is a leading American multinational pharmaceutical and biotechnology corporation established in 1849 by Charles Pfizer and his cousin Charles F. Erhart. Pfizer stands as one of the world's largest pharmaceutical companies, with annual sales nearing $50 billion, excluding COVID-19 product sales.

Pfizer's core business revolves around the development, manufacturing, and global distribution of prescription drugs and vaccines. Its top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. These products contribute significantly to Pfizer's global sales, with nearly 50% of revenues coming from international markets, and emerging markets playing a crucial role.

In recent news, Pfizer continues to make strides in cancer treatment through its collaboration with Astellas and Merck. A key focus has been on the promising cancer therapeutic combinations involving PADCEV™ (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab), targeting metastatic urothelial cancer. This collaboration underscores Pfizer's commitment to advancing cancer treatments and improving patient outcomes worldwide.

Financially, Pfizer remains robust, continually investing in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs. Strategic partnerships and collaborations further enhance its position in the market, ensuring a steady pipeline of new and effective therapeutic solutions.

With a rich history and a steadfast commitment to healthcare innovation, Pfizer Inc. continues to be a significant player in the pharmaceutical industry, dedicated to improving global health through advanced medical research and groundbreaking therapies.

News

ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV

Rhea-AI Summary
ViiV Healthcare, a leading HIV specialist company, presented 64 abstracts at CROI 2024, showcasing advancements in their pipeline and portfolio, including ultra long-acting medicines, broadly neutralising antibodies, and real-world evidence. Key highlights include phase I study results of cabotegravir formulations, phase IIa findings of VH3810109, and interim analysis of the LATITUDE trial showing superior efficacy of Cabenuva over daily oral standard of care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences
-
News

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Rhea-AI Summary
Pfizer Inc. (PFE) will host a webcast with CFO David Denton at the TD Cowen 44th Annual Health Care Conference on March 4, 2024. The webcast will be available for replay for at least 90 days on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
conferences
-
News

Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

Rhea-AI Summary
Pfizer Inc. and Everest Medicines' partner, Pfizer Inc., received marketing authorization from the European Commission for VELSIPITY® (etrasimod) in the EU to treat ulcerative colitis patients 16 years and older. The approval is based on positive Phase 3 data and offers a convenient once-daily oral treatment option for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
News

European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

Rhea-AI Summary
Pfizer Inc. receives marketing authorization from the European Commission for VELSIPITY, the first oral therapy for ulcerative colitis in the EU, targeting patients 16 years and older. The drug is approved for patients with moderately to severely active UC who haven't responded well to conventional or biological therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day

Rhea-AI Summary
Pfizer Inc. (PFE) will host an Oncology Innovation Day to discuss its new Pfizer Oncology Division's strategic approach, robust portfolio, R&D capabilities, and growth potential until 2030. Investors can access the live webcast on February 29, 2024, and submit questions for the leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
News

ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)

Rhea-AI Summary
ViiV Healthcare, majority owned by GSK, with Pfizer and Shionogi as shareholders, announced the availability of Dovato in a blister pack in the U.S. Dovato is approved as a complete regimen to treat HIV-1 infection in adults with no ARV treatment history or to replace the current ARV regimen in those who are virologically suppressed. The blister pack aims to address challenges faced by the HIV community, offering discretion and portability for people living with HIV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
none
News

ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)

Rhea-AI Summary
ViiV Healthcare, a global specialist HIV company, has announced the availability of Dovato in a blister pack in the U.S. Dovato is approved as a complete regimen to treat HIV-1 infection in adults with no ARV treatment history or to replace the current ARV regimen in those who are virologically suppressed. The blister pack aims to address challenges faced by the HIV community, such as stigma and convenience, and offers a discreet package that may fit more seamlessly into people's daily routines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
none
-
News

Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities

Rhea-AI Summary
The American Cancer Society (ACS) and Pfizer Inc. (NYSE: PFE) have launched the 'Change the Odds: Uniting to Improve Cancer Outcomes' initiative, aiming to bridge the gap in cancer care disparities in medically underrepresented communities across the United States. Pfizer has committed $15 million in funding to enhance awareness of and access to cancer screenings, clinical trial opportunities, and patient support in these communities, with a focus on breast and prostate cancer. The initiative also aims to address barriers to accessing cancer screening and quality care in rural areas, with plans to engage additional partners to extend the program's reach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
none
-
News

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

Rhea-AI Summary
Genmab A/S and Pfizer, Inc. announced that the European Medicines Agency has validated the marketing authorization application of tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer. The application is based on data from the Phase 3 innovaTV 301 trial, demonstrating superior overall survival, progression-free survival, and objective response rate compared to chemotherapy. The safety profile was consistent with previous data. If approved, tisotumab vedotin would be the first ADC granted EU marketing authorization for cervical cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
News

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance

Rhea-AI Summary
Pfizer Inc. reported a significant decline in revenues for the fourth quarter and full-year 2023, with a 41% operational decrease in year-over-year revenues. The decline was driven by a decrease in Comirnaty and Paxlovid revenues, offset by growth in new product and indication launches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
earnings

FAQ

What is the current stock price of Pfizer (PFE)?

The current stock price of Pfizer (PFE) is $26.41 as of January 14, 2025.

What is the market cap of Pfizer (PFE)?

The market cap of Pfizer (PFE) is approximately 151.1B.

What is Pfizer Inc. known for?

Pfizer Inc. is known for its development, manufacturing, and distribution of prescription drugs and vaccines, including Prevnar 13, Ibrance, and Eliquis.

Where is Pfizer's headquarters located?

Pfizer's headquarters are located at The Spiral in Manhattan, New York City.

How much does Pfizer make annually?

Pfizer's annual sales are close to $50 billion, excluding COVID-19 product sales.

What are some of Pfizer's top-selling products?

Some of Pfizer's top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis.

What is the significance of Pfizer's international sales?

Pfizer's international sales represent nearly 50% of its total sales, with emerging markets being a major contributor.

What recent collaborations has Pfizer been involved in?

Pfizer has recently been involved in collaborations with Astellas and Merck to develop and commercialize cancer treatments like PADCEV™ and KEYTRUDA®.

When was Pfizer founded?

Pfizer was founded in 1849 by Charles Pfizer and Charles F. Erhart.

What is Pfizer's approach to innovation?

Pfizer continually invests in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs.

How does Pfizer contribute to cancer treatment?

Pfizer contributes to cancer treatment through its development of innovative therapies and strategic collaborations, notably involving PADCEV™ and KEYTRUDA®.

What role do strategic partnerships play for Pfizer?

Strategic partnerships enhance Pfizer's market position, ensuring a steady pipeline of new and effective therapeutic solutions.
Stock PFE logo
Pfizer Inc.

NYSE:PFE

PFE Rankings

#70 Ranked by Market Cap
#420 Ranked by Dividends

PFE Stock Data

151.15B
5.66B
0.05%
67.79%
1.51%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NEW YORK